In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

P fizer and Astella’s Padcev (enfortumab vedotin) and MSD’s Keytruda (pembrolizumab) administered perioperatively extended ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced ...

In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...

Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Pfizer’s Padcev plus Keytruda combo shows significant survival gains in muscle‑invasive bladder cancer and could become ...

Search for Symbols, analysts, keywords Log in PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer ...